22nd Century Group, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by 22nd Century Group, Inc., a Nevada corporation, on December 30, 2011, reporting events occurring on December 26, 2011. The company is based in Clarence, New York, and operates in the pharmaceutical sector, specifically focusing on smoking cessation aids.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
The material event reported is the issuance of a press release on December 26, 2011, detailing the preliminary results of the Phase II-B clinical trial for the company's smoking cessation aid, X-22. No financial changes versus prior periods are disclosed in this document.
Outlook, Risks, and Management Commentary
Management commentary is limited to the announcement of the clinical trial results. The filing does not provide specific guidance, future outlook, risk factors, or contingencies beyond the reference to the attached press release (Exhibit 99.1). The significance of the trial results is not detailed within the body of the 8-K.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for specific data on the Phase II-B clinical trial results for X-22.
- Verify the statistical significance and safety profile of the trial results mentioned in the press release.
- Check subsequent filings for any regulatory updates or FDA communications regarding the X-22 product.
- Confirm the company's current cash position and runway, as this 8-K does not disclose liquidity status.